S&P Futures
4,258.50+2.50(+0.06%)Dow Futures
34,197.00+115.00(+0.34%)Nasdaq Futures
14,343.75-10.50(-0.07%)
Inventiva S.A. (IVA)
Chart Events
Performance Outlook
| Previous Close | 13.90 |
| Open | 13.71 |
| Bid | 13.46 x 900 |
| Ask | 19.00 x 1300 |
| Day's Range | 13.53 - 13.92 |
| 52 Week Range | 9.01 - 19.06 |
| Volume | 11,703 |
| Avg. Volume | 18,932 |
| Market Cap | 543.076M |
| Beta (5Y Monthly) | 0.91 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Related Research
- GlobeNewswire
Inventiva to participate at the SVB Leerink CybeRx Series: Liver Disease Day
Daix (France), June 15, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that the Company will participate to the upcoming SVB Leerink CybeRx Series: Liver Disease Day, being held virtually on June 17, 2021. During the event, members of
- GlobeNewswire
Inventiva announces three scientific presentations at the EASL International Liver Congress™ 2021 and during a KOL webcast event
Two oral presentations showing the beneficial effects of lanifibranor on cardiovascular risk biomarkers in patients with NASHthe positive effects of lanifibranor on several biomarkers of disease activity and associated risks in patients with NASH and F2/F3 fibrosis One poster presentation showing the beneficial effects of the combination treatment of lanifibranor and ACC1/2 inhibitor firsocostat from GileadInventiva will host a dedicated Key Opinion Leader (KOL) webcast event for investors and a
- GlobeNewswire
Inventiva to participate at the Jefferies Virtual Healthcare Conference
Daix (France), May 25, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that the Company will participate to the upcoming Jefferies Virtual Healthcare Conference, being held virtually on June 1-4, 2021. During the event, members of the Company’s leadership will present a corporate overview, participate in a fireside chat and engage in 1x1 investor meetings. The event details are as follows: Date: Thursday, June 3, 2021Time: 9:00 am – 9:25 pm (ET) / 3:00 pm – 3:25 pm (CET)Participants: Frédéric Cren, Chairman, CEO and cofounder of Inventiva, and David Nikodem, Vice President of US Operations of InventivaFormat: Video presentationLive and replay link: https://wsw.com/webcast/jeff174/iva/1694304 The presentation document and the above link will also be available on Inventiva’s website in the “Investors” – “Investor Presentations” section. About Inventiva Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, MPS and other diseases with significant unmet medical need. Leveraging its expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation, Inventiva is currently advancing two clinical candidates, as well as a deep pipeline of earlier stage programs. Lanifibranor, its lead product candidate, is being developed for the treatment of patients with NASH, a common and progressive chronic liver disease for which there are currently no approved therapies. In 2020, Inventiva announced positive topline data from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH and obtained Breakthrough Therapy and Fast Track designation for lanifibranor in the treatment of NASH. Inventiva is also developing odiparcil, a second clinical stage asset, for the treatment of patients with subtypes of MPS, a group of rare genetic disorders. Inventiva announced positive topline data from its Phase IIa clinical trial evaluating odiparcil for the treatment of adult MPS VI patients at the end of 2019 and received FDA Fast Track designation in MPS VI for odiparcil in October 2020. In parallel, Inventiva is in the process of selecting an oncology development candidate for its Hippo signalling pathway program. Furthermore, the Company has established a strategic collaboration with AbbVie in the area of autoimmune diseases. AbbVie has started the clinical development of ABBV‑157, a drug candidate for the treatment of moderate to severe psoriasis resulting from its collaboration with Inventiva. This collaboration enables Inventiva to receive milestone payments upon the achievement of pre-clinical, clinical, regulatory and commercial milestones, in addition to royalties on any approved products resulting from the collaboration. The Company has a scientific team of approximately 70 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, as well as in clinical development. It also owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly‑owned research and development facility. Inventiva is a public company listed on compartment C of the regulated market of Euronext Paris (ticker: IVA - ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.com Contacts InventivaPascaline ClercVP of Global External Affairsmedia@inventivapharma.com+1 240 620 9175Brunswick GroupYannick Tetzlaff / Tristan Roquet Montegon / Aude LepreuxMedia relationsinventiva@brunswickgroup.com+33 1 53 96 83 83Westwicke, an ICR CompanyPatricia L. BankInvestor relationspatti.bank@westwicke.com+1 415 513 1284 Attachment Inventiva - PR - Jefferies Virtual Healthcare Conference - EN - 25 05 2021
